Glasswing Ventures

Gilde Healthcare is a Utrecht, Netherlands-based venture capital firm focused on life sciences and healthcare companies, founded in 2001 and investing across seed, Series A, and Series B stages in biopharmaceutical, medical technology, and diagnostics companies primarily in Europe. The firm has established itself as one of the most active and respected healthcare venture investors in continental Europe, applying deep scientific and clinical diligence to identify drug candidates, medical devices, and health technology companies where Europe's world-class research base has produced breakthrough innovations. Gilde Healthcare invests with initial checks from $5 million to $20 million. Portfolio companies include uniQure, the Dutch gene therapy company that completed a Nasdaq IPO in 2014 as one of the first commercial gene therapy companies; Acorai, a non-invasive cardiac pressure monitoring company; AM-Pharma, the clinical-stage company developing treatments for sepsis-related acute kidney injury; and Curasept, a dental and oral health company. Beyond its original investments, the portfolio includes additional European clinical-stage biopharmaceutical and medical device companies.